Orphan Drug Opportunities Acasti is focused on three underserved orphan diseases with FDA Orphan Drug Designations, offering seven years of marketing exclusivity post-launch in the US, presenting a protected market window for potential partnerships and licensing deals.

Late-Stage Delivery Platform The company emphasizes novel drug delivery technologies that can improve onset, efficacy, and safety of existing therapies, creating cross selling opportunities with partners seeking to enhance current drug performance or expand indications.

Strategic Partnerships Active collaboration with regulatory bodies and contract development organizations (CDOs) for pivotal trials such as STRIVE-ON in aSAH, highlighting potential for co-development, clinical milestones, and shared risk models with interested buyers or licensors.

Financial and Investment Signals With private placements and a funding level around $108M, plus reported revenue activity, there is appetite from investors and strategic buyers for portfolio milestones, making it feasible to propose strategic alliances, license-in, or buyout discussions.

Market Validation Recent leadership hires and engagement in investor events, along with ongoing Phase 3 safety trial activities for GTX-104, indicate momentum and credibility that can facilitate dialogs with large pharma seeking late-stage assets or add-ons in neurology and rare disease spaces.